Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20395893 | 0.95 | MAPT (0.44) | CA1CA2KDM4EGAABLM | |
| Hydrogen Sulfide SCHEMBL20395882 | 0.94 | MAPT (0.43) | CA1CA2KDM4EGAABLM | |
| SCHEMBL644117 | 0.92 | MAPT (0.44) | CA1CA2KDM4EGAABLM | |
| SCHEMBL4873232 | 0.88 | ADRB2 (0.40) | CA1CA2KDM4EGAABLM | |
| SCHEMBL2530033 | 0.87 | ATM (0.41) | CA1CA2KDM4EGAABLM | |
| SCHEMBL19511448 | 0.87 | MEN1 (0.51) | CA1CA2KDM4EADRB2ADRB1 | |
| SCHEMBL642424 | 0.86 | CA12 (0.56) | CA1CA2KDM4EGAABLM | |
| SCHEMBL4878299 | 0.86 | KAT6A (0.51) | CA1CA2KDM4EGAABLM | |
| SCHEMBL2527989 | 0.86 | CREBBP (0.41) | CA1CA2KDM4EGAABLM | |
| SCHEMBL2525888 | 0.86 | FFAR1 (0.45) | CA1CA2KDM4EBLMADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365501-A1 | 4-METHOXY-2-PHENETHYL ISOINDOLINE-1-ONE DERIVATIVE AND COMPOSITION FOR TREATING NEUROLOGICAL DISEASES, COMPRISING SAME | CNG BIO CO., LTD. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230365501-A1 | 4-METHOXY-2-PHENETHYL ISOINDOLINE-1-ONE DERIVATIVE AND COMPOSITION FOR TREATING NEUROLOGICAL DISEASES, COMPRISING SAME | CNG BIO CO., LTD. (KR) | 2023-11-16 | — | — | US | disclosed |
| EP-4223742-A1 | 4-METHOXY-2-PHENETHYL ISOINDOLINE-1-ONE DERIVATIVE, AND COMPOSITION FOR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME | CNG Bio Co., Ltd. (KR) | 2023-08-09 | — | — | EP | disclosed |
| WO-2022065823-A1 | 4-METHOXY-2-PHENETHYL ISOINDOLINE-1-ONE DERIVATIVE, AND COMPOSITION FOR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME | 씨엔지바이오 주식회사 | 2022-03-31 | — | — | WO | disclosed |
| US-10822349-B2 | Macrocyclic purines for the treatment of viral infections | Janssen Sciences Ireland Unlimited Company (IE) | 2020-11-03 | — | — | US | disclosed |
| US-20190330234-A1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2019-10-31 | — | — | US | disclosed |
| US-10280180-B2 | Macrocyclic purines for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2019-05-07 | — | — | US | disclosed |
| EP-2872515-B1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-08 | — | — | EP | disclosed |
| US-20150299221-A1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | Janssen Sciences Ireland Unlimited Company (IE) | 2015-10-22 | — | — | US | disclosed |
| US-20150299221-A1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | Janssen Sciences Ireland Unlimited Company (IE) | 2015-10-22 | — | — | US | disclosed |
| EP-2010520-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | Pfizer Products Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-06-05 | — | — | US | disclosed |
| EP-1851208-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-11-07 | — | — | EP | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2006074950-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
| US-4143055-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS | GRUPPO LEPETIT S.P.A. (IT) | 1979-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330234-A1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | PNP, HPRT1, UMPS | CA1 4858/4885CA2 4544/4885KDM4E 2444/4885 |
| US-20230365501-A1 | 4-METHOXY-2-PHENETHYL ISOINDOLINE-1-ONE DERIVATIVE AND COMPOSITION FOR TREATING NEUROLOGICAL DISEASES, COMPRISING SAME | NGF, BDNF, NTRK2 | CA1 3869/4885CA2 3616/4885KDM4E 874/4885 |
| US-10280180-B2 | Macrocyclic purines for the treatment of viral infections | PNP, HPRT1, UMPS | CA1 4858/4885CA2 4544/4885KDM4E 2444/4885 |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | GCK, GCKR, HK1 | CA1 1547/4885CA2 574/4885KDM4E 1790/4885 |
| US-20150299221-A1 | MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS | PNP, HPRT1, UMPS | CA1 4858/4885CA2 4544/4885KDM4E 2444/4885 |
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | BACE1, BACE2, APP | CA1 151/4885CA2 184/4885KDM4E 3337/4885 |
| US-10822349-B2 | Macrocyclic purines for the treatment of viral infections | PNP, HPRT1, UMPS | CA1 4858/4885CA2 4544/4885KDM4E 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.